Board of Directors
Larry McCarthy, PhD, Executive Chairman of the Board
Dr. McCarthy serves as the Executive Chairman of Primera Diagnostics. He currently is a Venture Partner with Ampersand Ventures and is also a member of the Boards of Directors of IBT Laboratories, Genoptix , Magellan Biosciences, and Marligen Biosciences. Previously, he served as Chairman, CEO and CTO of Focus Diagnostics; as President of Boehringer Mannheim Diagnostics; and as VP of R&D and VP and General Manager at Becton Dickinson & Company. Dr. McCarthy has also served on the faculties of the Cornell University School of Medicine, the University of North Carolina School of Medicine, and the Johns Hopkins School of Medicine. He has directed clinical laboratories at the Memorial Sloan-Kettering Cancer Center and at the North Carolina Memorial Hospital.
Robert J. Rosenthal, PhD, President & CEO, Magellan Biosciences
Mr. Rosenthal is Magellan's founding president and chief executive officer. A proven executive, Dr. Rosenthal has 20 years of experience building value for customers, shareholders, and employees in companies serving the biomedical research and diagnostics industries. Most recently, Dr. Rosenthal was president and CEO of Boston Life Sciences, an R&D development-stage biopharmaceutical company. Previously, he was president of PerkinElmer's Instruments division, where he managed the acquisition and integration of the Analytical Instruments group from PE Corporation. As president and CEO of Thermo Optek, Dr. Rosenthal built a market-leading instrument company, which went public in 1996. Prior to Thermo Optek, Dr. Rosenthal served as president of Nicolet Instrument Corporation, a subsidiary of Thermo Instruments, which supplies analytical tools for research and development to several industries, including biotechnology. In addition to the Magellan and subsidiary boards, Dr. Rosenthal serves on several others, including the boards of Matritech (AMEX:MZT), Safeguard Scientifics, Inc. (NYSE:SFE), and the University of Maryland Department of Chemistry and Biochemistry Board of Advisors. He is also a member of the University of Maryland, College of Chemical and Life Sciences Board of Visitors.
Dr. Rosenthal holds a BS in chemistry from the University of Maryland, an MS in chemistry from State University of New York (Buffalo), and a PhD in physical chemistry from Emory University. He spent a year in Germany completing a post-doctoral fellowship and as a guest scientist of the Alexander von Humboldt Foundation. This was followed by an additional post-doctoral fellowship at UCLA. Dr. Rosenthal also holds an AEA Executive MBA from Stanford University.
Ron invests in the biotechnology and molecular diagnostic sectors. He has served on the boards of eighteen companies including General Surgical Innovations, Inc. (acquired by Tyco International Corp.), GeneOhm Sciences, Inc. (acquired by Becton Dickinson), Protometrix, Inc. (acquired by Invitrogen Corp.), and Applied Molecular Evolution Inc. (acquired by Eli Lilly). He was founding CEO of Protometrix, Inc. as well as of CGI Pharmaceuticals, Inc. Ron currently serves as the Chairman of the Board of OpGen, Inc. and on the boards of BIKAM Pharmaceuticals, Inc. and BioRelix, Inc. Prior to the founding of CHL Medical Partners, Ron was a general partner at Hancock Venture Partners (now HarbourVest Partners) where he invested in sixteen healthcare companies, ten of which had successful IPOs. Ron graduated from the University of Glasgow with a B.Sc. in Molecular Biology, Oxford University where he received a D.Phil. in Cell Biology and the Wharton School of the University of Pennsylvania.
Vincent Miles PhD, Venture Partner, Abingworth
Mr. Miles has more than 25 years of management experience in the biotechnology industry. He was most recently Senior Vice President, Business Development, of the Abingworth portfolio company, Alnylam Pharmaceuticals. Before joining Alnylam, Vincent was at Millennium Pharmaceuticals where he held a number of senior management positions in business development, strategic planning and corporate communications. Formerly he was Director of the technology transfer office at the Dana-Farber Cancer Institute and held senior management positions in business development and research at RiboGene and Pharmacia, having begun his career at Amersham International in R&D. He has a BSc in biochemistry and a PhD in molecular biology from University College London. He is based in the Boston office.
Mr. Norhalim Yunus is the Chief Executive Officer of Malaysian Technology Development Corporation (MTDC) Sdn. Bhd., a venture capital company which is a wholly owned subsidiary of Khazanah Nasional Berhad, the investment holding arm of the Government of Malaysia. MTDC is co-manager of the Malaysian Life Sciences Capital Fund (MLSCF) together with Burrill & Co which invests in life sciences companies globally. Norhalim has been with MTDC since 1993 and prior to joining MTDC he was with the research and advisory arm of Kumpulan Guthrie Berhad, the oil palm conglomerate. He is also a council member of the Malaysian Venture Capital Development Council. Norhalim is a biologist by training.
Prior to joining Interwest, Nina was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a healthcare-focused fund. She began her career conducting health policy and survey research with the Kaiser Family Foundation. Nina is a board member of Alyine Pharmaceuticals, she is an observer on the boards of AkaRx Inc., Devax Inc., Kanisa Pharmaceuticals and MacuSight Inc., Nina also played a primary role in Interwest’s investment in Aspreva Pharmaceuticals. She holds a B.S. in human biology from Stanford University.